Market Overview

Asia-Pacific (APAC)Non-Small Cell Lung Cancer Therapeutics Markets growing at a CAGR of 8.7%, will be valued at $4.9 billion in 2022: ResearchMoz


Albany, NY, June 01, 2016 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations. 

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Xalkori and Gilotrif. Opdivo (nivolumab) - a mAb immune checkpoint inhibitor targeted towards Programmed cell Death (PD) 1 - is a recent market entrant, gaining approval for treating advanced or metastatic squamous NSCLC patients in Japan in 2015 and in Australia in 2016. 

For more info, get a Sample PDF: 

While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. Therapies that target mutant T790M and KRAS are being developed in the pipeline, with osimertinib, targeting T790M, gaining approval in Japan in 2016.


The NSCLC Asia-Pacific market will be valued at $4.9 billion in 2022, growing from $2.7 billion in 2015 at a CAGR of 8.7%. 

  • How will immunotherapies such as Keytruda contribute to the growth?
  • What effect will patent expirations of currently branded therapies have on market value? 

The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies. 

  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
  • What implications will the increased focus on targeted therapies have on the future of NSCLC treatment? 

View TOC (table of content), Figures and Tables of the Report: 

Reasons to Buy - 

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies. 

About Us 

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Mr.Nachiket Ghumare State Tower, 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-621-2074 USA - Canada Toll Free: 866-997-4948 Website:

Primary Logo

View Comments and Join the Discussion!